Malathi Raman

Learn More
BACKGROUND Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process. OBJECTIVES To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind,(More)
Development of complications is very common among the patients suffering from Plasmodium falciparum infection. A total of 64 patients of Plasmodium falciprum infections were admitted to the District Hospital, Ukhrul, during the period of 1st May 1996 to 15th June 1999; 9.37% patients do not develop complication while the rest 90.63% developed one or more(More)
BACKGROUND OX40 (CD134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK4083 is a fully human monoclonal antibody against OX40. OBJECTIVE The primary aim of this first-in-human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK4083 in patients with mild to moderate plaque psoriasis.(More)
BACKGROUND Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown. OBJECTIVES Tofacitinib, a small-molecule JAK inhibitor, was investigated for the topical treatment of(More)
  • 1